Diagnostic Worth Of T₂ Mapping And T₂^* Mapping Fix The Amount In Benign And Malignant Prostatic Lesions

Objective To study the feasibility of applying T₂ mapping and T₂^* mapping quantitative techniques in prostate lesions under GE 3.0T MRI,by measuring the quantitative values of T₂ mapping and T₂^* mapping of benign and malignant prostate lesions,analyze the difference between benign and malignant prostate quantitative values,the approximate range of benign and malignant critical values was preliminarily established,thus providing certain clinical basis for the diagnosis and differential diagnosis of benign and malignant lesions of prostate.Methods According to the inclusion and exclusion criteria,a total of 50patients were included in the study,including 19 patients with malignant prostate disease,The average age was（71.79±9.35）years,ranging from（59 to 90）years,and prostate specific antigen（PSA）was（8.9～>100）ng/m L.There were 31 patients with benign prostatic lesions,the age ranged from（51 to 81）years,with an average of（66.06±9.03）years,and the prostate specific antigen was（0.2～59.92）ng/ml.MRI images of the patients were analyzed independently by two radiologists.On the basis of prostate imaging reporting and data system version2.0（PI-RADSv2）,to measure the suspicious lesions by lesions T₂ mapping and T₂^* mapping quantitative values.All the included cases had major pathology or ultrasound-guided puncture biopsy pathology.All patients underwent routine MRI examinations（including T₁WI,T₂WI transverse,T₂WI coronal,T₂WI sagittal and T₂WI transverse lipocompression sequences）and T₂ mapping and T₂^* mapping examinations to measure the quantitative values of T₂ mapping and T₂^* mapping in benign and malignant prostate lesions,and analyze the differences between the two values.Professional statistical software（SPSS 25.0）was used for analysis.The independent sample t-test and Mann-Whitney U test to compare different T₂ mapping of benign and malignant lesions of the prostate and T₂^* mapping quantitative value differences,adopt the receiver-operating characteristics（ROC）curve was drawn to determine the optimal diagnostic threshold value of benign and malignant prostate lesions,as well as its sensitivity and specificity.The area of ROC curve（AUC）was used to evaluate the diagnostic efficacy of T₂ mapping and T₂^* mapping quantitative values for benign and malignant prostate lesions.Results The quantitative values of T₂ mapping and T₂^* mapping were successfully measured in all the 50 patients included in the study.Ultrasound-guided puncture biopsy confirmed 3 cases of prostate cancer and 9cases of benign prostate lesions.There were 16 cases of prostate cancer and22 cases of benign prostate disease confirmed by operation and pathology.The T₂ mapping quantitative value of benign prostate lesions was（75.54～111.44）ms,with an average of（93.15±11.17）ms.The quantitative value of T₂ mapping for prostate malignant lesions was（63.57～84.67）ms,with an average of（74.50±6.93）ms.The difference of T₂ mapping quantitative value in benign and malignant prostate lesions was statistically significant（p<0.01）.The best cutoff value of T₂ mapping was 77.49ms,and the AUC was 0.91.The sensitivity and specificity of benign and malignant prostate lesions were68.4%/96.8%,respectively.The T₂^* mapping quantitative value of benign prostate lesions was（18.25～66.67）ms,with an average of（43.21±15.39）ms.The T₂^* mapping quantitative value of prostate malignant lesions was（12.67-42.50）ms,with an average of（21.53±6.81）ms.The difference of T₂^* mapping quantitative value in benign and malignant prostate lesions was statistically significant（p<0.01）.The best cutoff value of T₂^* mapping was31.66ms,and the AUC was 0.88.The sensitivity and specificity of benign and malignant prostate lesions were 94.7%/74.2%,respectively.Conclusion The quantitative value of T₂ mapping and T₂^* mapping is helpful to distinguish benign and malignant lesions of prostate,which meets the objective quantitative requirements of clinical,and is a good supplement to the sequence of prostate magnetic resonance examination.